Trend of Improving Prognosis of Hepatocellular Carcinoma in Clinical Practice: An Italian In-Field Experience

被引:11
作者
Borzio, Mauro [1 ]
Dionigi, Elena [1 ]
Rossini, Angelo [2 ]
Toldi, Anna [3 ]
Francica, Giampiero [4 ]
Fornari, Fabio [5 ]
Salmi, Andrea [6 ]
Farinati, Fabio [7 ]
Vicari, Susanna [8 ]
Marignani, Massimo [9 ]
Terracciano, Fulvia [10 ]
Ginanni, Barbara [11 ]
Sacco, Rodolfo [11 ]
机构
[1] AO Melegnano, UOC Gastroenterol, Melegnano, Italy
[2] Osped Civile Brescia, UOD Epatol, Brescia, Italy
[3] Osped Valduce, UOC Gastroenterol, Como, Italy
[4] UO Ecointerventist, Dipartimento Diagnost Immagini, Castelvolturno, Italy
[5] Osped Saliceto, UOC Gastroenterol, Piacenza, Italy
[6] Poliambulanza, UOC Gastroenterol, Brescia, Italy
[7] Univ Padua Polyclin, UOC Gastroenterol, Dipartimento Sci Chirurg & Gastroenterol, Padua, Italy
[8] Osped Bentivoglio, UOC Gastroenterol, Bologna, Italy
[9] Osped S Andrea, UOC Gastroenterol, Rome, Italy
[10] Osped SanGiovanni Rotondo, UOC Gastroenterol, San Giovanni Rotondo, Italy
[11] Osped Cisanello, UOC Gastroenterol, Pisa, Italy
关键词
Liver neoplasms; Cirrhosis; Epidemiology; Surveillance; Survival; Treatment; RADIOFREQUENCY ABLATION; AMERICAN ASSOCIATION; UNITED-STATES; SURVEILLANCE; OUTCOMES; MANAGEMENT; RESECTION; SURVIVAL; THERAPY; EUROPE;
D O I
10.1007/s10620-014-3427-5
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Recent data suggest that outcome of hepatocarcinoma is improving. Aims In order to explore whether survival is also increasing in clinical practice, we compared two multicenter independent in-field cohorts of cirrhotics with newly diagnosed HCCs. Methods Cohort 1 (C1) consisted of 327 patients enrolled between January and December 1998, and cohort 2 (C2) included 826 patients enrolled between September 2008 and November 2012. Patients were stratified according to Child-Pugh score, MELD score, and HCC staged according to TNM, BCLC systems. Results At baseline, C2 patients were significantly older, with more frequent comorbidities and better liver function. In C2, HCC was more frequently detected under regular ultrasound surveillance (P < 0.001), BCLC early stages were more frequent, and rates of smaller and uni/paucinodular tumors were significantly higher. Treatment of any type was more frequently offered to C2 patients (P < 0.001). Proportion of patients treated by TACE increased, and radiofrequency ablation was the most used ablative treatment. Survival rate was significantly higher in C2 being C1 and C2 survival at 1-3 years 72-25 and 75-44 %, respectively. Child-Pugh score A, BCLC stage A, single nodule, size <= 3 cm, belonging to cohort C2 and treatment per se independently predicted survival. Conclusions This in-field study showed a trend on improved HCC outcomes over time, which seems to be mainly due to a better presentation thanks to the wider application of surveillance and increased propensity to treat patients. These encouraging data should support further efforts to implement such approach to HCC in everyday clinical practice.
引用
收藏
页码:1465 / 1473
页数:9
相关论文
共 29 条
[1]   Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis [J].
Bolondi, L ;
Sofia, S ;
Siringo, S ;
Gaiani, S ;
Casali, A ;
Zironi, G ;
Piscaglia, F ;
Gramantieri, L ;
Zanetti, M ;
Sherman, M .
GUT, 2001, 48 (02) :251-259
[2]   Epidemiology and outcome of hepatocellular carcinoma in Lombardy [J].
Borzio, M. ;
Colloredo, G. ;
Pioltelli, P. ;
Quaghliuolo, M. .
DIGESTIVE AND LIVER DISEASE, 2007, 39 (11) :1011-1017
[3]  
Borzio M, 2013, FUTURE ONCOL, V9, P283, DOI [10.2217/FON.12.183, 10.2217/fon.12.183]
[4]   Primary liver cancer:: Worldwide incidence and trends [J].
Bosch, FX ;
Ribes, J ;
Díaz, M ;
Cléries, R .
GASTROENTEROLOGY, 2004, 127 (05) :S5-S16
[5]   Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004 [J].
Bosetti, Cristina ;
Levi, Fabio ;
Boffetta, Paolo ;
Lucchini, Franca ;
Negri, Eva ;
La Vecchia, Carlo .
HEPATOLOGY, 2008, 48 (01) :137-145
[6]   Management of hepatoceullular carcinoma [J].
Bruix, J ;
Sherman, M .
HEPATOLOGY, 2005, 42 (05) :1208-1236
[7]   Hepatocellular carcinoma: Trends of incidence and survival in Europe and the United States at the end of the 20th century [J].
Capocaccia, Riccardo ;
Sant, Milena ;
Berrino, Franco ;
Simonetti, Arianna ;
Santi, Valentina ;
Trevisani, Franco .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 (08) :1661-1670
[8]   Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].
Cheng, Ann-Lii ;
Kang, Yoon-Koo ;
Chen, Zhendong ;
Tsao, Chao-Jung ;
Qin, Shukui ;
Kim, Jun Suk ;
Luo, Rongcheng ;
Feng, Jifeng ;
Ye, Shenglong ;
Yang, Tsai-Sheng ;
Xu, Jianming ;
Sun, Yan ;
Liang, Houjie ;
Liu, Jiwei ;
Wang, Jiejun ;
Tak, Won Young ;
Pan, Hongming ;
Burock, Karin ;
Zou, Jessie ;
Voliotis, Dimitris ;
Guan, Zhongzhen .
LANCET ONCOLOGY, 2009, 10 (01) :25-34
[9]   Utilization and Outcomes of Palliative Therapy for Hepatocellular Carcinoma A Population-based Study in the United States [J].
Davila, Jessica A. ;
Duan, Zhigang ;
McGlynn, Katherine A. ;
El-Serag, Hashem B. .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2012, 46 (01) :71-77
[10]   Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: A population-based study [J].
El-Serag, HB ;
Siegel, AB ;
Davila, JA ;
Shaib, YH ;
Cayton-Woody, M ;
McBride, R ;
McGlynn, KA .
JOURNAL OF HEPATOLOGY, 2006, 44 (01) :158-166